Literature DB >> 29896007

Combined Cabergoline and Metformin in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: Methodological Concerns.

Ahmed Mohamed Abbas1.   

Abstract

Entities:  

Year:  2018        PMID： 29896007      PMCID： PMC5972097          DOI： 10.1007/s13224-018-1121-9

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN： 0975-6434


× No keyword cloud information.
  4 in total

Review 1.  Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review.

Authors:  Maria-Elena Lautatzis; Dimitrios G Goulis; Maria Vrontakis
Journal:  Metabolism       Date:  2013-07-23       Impact factor: 8.694

2.  The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia.

Authors:  Robert Krysiak; Karolina Kowalcze; Witold Szkrobka; Boguslaw Okopien
Journal:  Eur J Intern Med       Date:  2016-02-05       Impact factor: 4.487

Review 3.  The prevention of ovarian hyperstimulation syndrome.

Authors:  Shannon Corbett; Doron Shmorgun; Paul Claman
Journal:  J Obstet Gynaecol Can       Date:  2014-11

4.  Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial.

Authors:  Mervat Ali Mohamed Elsersy
Journal:  J Obstet Gynaecol India       Date:  2017-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.